We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Successful use of an antithrombin for heparin resistance with andexanet alfa.
- Authors
Honda, Jun; Itakura, Yuya; Tanaka, Shiori; Inoue, Satoki
- Abstract
Keywords: Andexanet alfa; Heparin resistance; Antithrombin; Activated coagulation time; Edoxaban EN Andexanet alfa Heparin resistance Antithrombin Activated coagulation time Edoxaban 1 3 3 05/19/23 20230517 NES 230517 To the Editor, Andexanet alfa neutralizes the anticoagulant effects of direct factor Xa inhibitors [[1]]. When performing surgery using heparin in patients who have received andexanet alfa, it is necessary to administer AT and confirm its anticoagulant effect by monitoring ACT and TEG, because of the possibility of heparin resistance. We herein report a case in which heparin resistance occurred as a result of andexanet alfa, but thrombus formation during cardiopulmonary bypass (CPB) was prevented by antithrombin (AT) administration and monitoring both activated coagulation time (ACT) and thromboelastography (TEG).
- Subjects
HEPARIN; CARDIOPULMONARY bypass; INFORMED consent (Medical law); ORAL medication
- Publication
JA Clinical Reports, 2023, Vol 9, Issue 1, p1
- ISSN
2363-9024
- Publication type
Article
- DOI
10.1186/s40981-023-00619-7